Save the Date: Emerging Considerations for the Role of Biomarker-Driven Immunotherapy in Upper GI Cancers

Upper gastrointestinal (GI) cancers are often undetected until late stages, leading to a poor prognosis. Treatment may be delayed or inappropriately assigned due to a lack of robust biomarker testing. To optimize patient outcomes, oncology clinicians must confidently possess a comprehensive understanding of predictive biomarkers, current and emerging therapies, clinical findings and implications of recent trial data, guideline updates, and the roles and responsibilities of the multidisciplinary team (MDT). It is crucial that this knowledge be applied in practice to make informed treatment decisions and reach optimal outcomes.

In this CE Concepts live webcast, expert faculty will discuss utilizing biomarker tests to select therapeutic approaches for patients with upper GI cancers, implementing current guidelines and recent clinical evidence to individualize treatment, and integrating an MDT approach to deliver high-quality disease management.

At the conclusion of this activity, learners will be able to better:

• Utilize pertinent biomarker tests to select therapeutic approaches for patients diagnosed with upper GI cancers
• Implement current expert guidelines and recent clinical evidence to individualize treatment for upper GI cancers
• Integrate a multidisciplinary approach to optimize the management of upper GI cancers

This educational activity is supported by an independent educational grant from Bristol Myers Squibb.

Pathologists, medical oncologists, surgical oncologists, nurse practitioners (NPs), physician associates (PAs), nurses, and pharmacists

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Margaret Wright, BSN, RN (Peer Reviewer)
Susan Perry (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.